Supplementary appendix: A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>A network meta-analysis of </b><b>immunotherapy-based treatments for </b><b>advanced nonsquamous non-small cell </b><b>lung cancer</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Additional Methodology:</b> 3</li><li><b>Figures:</b> 5</li><li><b>Tables:</b> 7</li><li><b>Inputs: </b>15</li><li><b>Results: </b>19</li><li><b>References:</b> 31</li></ul><p dir="ltr"><b>Introduction:</b> In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. <b>Materials & methods:</b> A systematic literature review of randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points. <b>Results: </b>Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than docetaxel.</p>